Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XRAY VISION: Xevinapant plus radiotherapy vs placebo plus radiotherapy in high-risk resected SCCHN ineligible for high-dose cisplatin
jRCT2011220014Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant + IMRT with Placebo + IMRT (2 arms). Primary endpoint: Disease-free survival. Started Sep 2022; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2011220014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220014.